Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Ngenla Prior Auth Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0577

    Growth Disorders - Ngenla Prior Authorization Policy

    Customize your policy alerts

    Sign up for Cigna Policy IP0577 alerts

    Get alerted when Policy IP0577 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Ngenla (somatrogon-ghla) for pediatric patients with growth failure due to inadequate growth hormone secretion, subject to the member’s benefit plan, applicable law, and the policy’s clinical and coding requirements.

    Policy Summary
    PayerCigna
    PolicyGrowth Disorders - Ngenla Prior Authorization Policy
    Policy CodePolicy IP0577
    Change TypeModified
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionUse preferred growth hormone products before requesting Ngenla, or document an applicable exception under the relevant preferred-product policy.
    SourceLink
    POLICY UPDATE CHANGES

    A preferred specialty management requirement was added before Ngenla approval.

    Pediatric growth hormone deficiency criteria were revised to add an alternative pathway using at least one subnormal stimulation test plus at least one growth hormone deficiency risk factor.

    Congenital hypopituitarism criteria were expanded to include stimulation-test, other-pituitary-hormone-deficiency, and characteristic imaging pathways.

    Preferred product requirements and preferred product tables were updated, and a Preferred Specialty Management Statement was added.

    The requirement to rule out or correct other pituitary hormone deficiencies before testing was removed.

    The brain radiation or tumor resection pathway was revised by removing the specified central nervous system pathology requirement.

    Continuation and switching criteria were updated for patients established on growth hormone therapy.

    Documentation requirements were added for continuation or switching therapy.

    The conditions-not-covered section was revised, and several previously listed conditions and off-label uses were removed.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    NgenlaCovered drug
    ≥3 to <18 yearsCovered age range
    1 yearInitial approval duration
    <10 ng/mLGrowth hormone response threshold
    ≥2 cm/yearContinuation height increase

    Ngenla Coverage Criteria

    Continuation therapy or switch from another growth hormone agent

    Approve for 1 year when the patient is currently receiving Ngenla or switching to Ngenla from another growth hormone agent, has been established on either therapy for ≥10 months, and meets ONE continuation pathway.

    ALL of the following

    • Patient is currently receiving Ngenla or is switching to Ngenla from another growth hormone agent and has been established on either therapy for ≥10 months.≥10 months
    • ONE continuation pathway

      • Patient is younger than 12 years and height increased by ≥2 cm/year in the most recent year.≥2 cm/year

        Documentation required.

      • Patient is ≥12 years and <18 years, height increased by ≥2 cm/year in the most recent year, and epiphyses are open.≥2 cm/year; open epiphyses

        Documentation required.

    Pediatric growth hormone deficiency

    The revised pediatric growth hormone deficiency pathway requires ALL of the following findings.

    Pediatric growth hormone deficiency pathway

    • Patient is at least 3 years of age and younger than 18 years.
    • At least one growth hormone stimulation test was performed using levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon, and the peak growth hormone response to at least one test was <10 ng/mL.<10 ng/mL

      Documentation required.

    • At least one growth hormone deficiency risk factor is present.

      Examples include downward crossing of two major height percentiles, growth below the expected rate for age and sex, low IGF-1 and/or IGFBP-3, a very low provocative-test peak as defined by the prescriber, growth velocity below the 10th percentile, status post craniopharyngioma resection, optic nerve hypoplasia, or a growth hormone gene deletion.

    Congenital hypopituitarism

    For congenital hypopituitarism, coverage is supported when the patient meets the condition requirement and ONE of the following qualifying findings is documented.

    Congenital hypopituitarism pathway

    • Patient has congenital hypopituitarism.
    • ONE qualifying finding

      • At least one growth hormone stimulation test was performed using levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon, and the peak growth hormone response to at least one test was <10 ng/mL.<10 ng/mL

        Documentation required.

      • Patient has a deficiency in at least one other pituitary hormone.

        Documentation required.

    Continuation or switching to Ngenla

    Continuation or switching to Ngenla requires established therapy and documentation of treatment response and skeletal maturity.

    Continuation or switching therapy

    • Patient is currently receiving Ngenla or is switching to Ngenla from another growth hormone agent and has been established on either therapy for at least 10 months.≥10 months
    • Documentation shows that height increased by at least 2 cm/year in the most recent year.≥2 cm/year

      Documentation required.

    • Epiphyses are open.

      Documentation required.

    Ngenla is not covered for athletic ability enhancement, athletic performance enhancement, or body building in non-athletes. Somatropin and related agents are not FDA-approved for these uses.

    Ngenla is not covered for central precocious puberty. Routine use of growth hormone in this setting is not recommended.

    Ngenla is not covered for congenital adrenal hyperplasia. Growth-promoting treatment for this condition may be considered only in appropriately controlled clinical trials when applicable.

    Ngenla is not covered for constitutional delay of growth and puberty. Somatropin does not increase adult height in these patients, whose adult height is usually normal.

    Use of Ngenla for any purpose other than the qualifying FDA-approved pediatric growth hormone deficiency indication is considered not medically necessary.

    Initial Pediatric Therapy

    Initial therapy for pediatric growth hormone deficiency

    Approve for 1 year when the pediatric patient is at least 3 years of age and younger than 18 years, meets ONE qualifying clinical pathway, and the required specialist and documentation conditions are satisfied.

    ALL of the following

    • Patient is at least 3 years of age and younger than 18 years.
    • ONE qualifying clinical pathway

      • Standard growth hormone deficiency: Patient meets the standard growth hormone deficiency pathway, including qualifying stimulation-test results, a qualifying height or height-velocity finding, and endocrinologist prescribing or consultation.

        Document stimulation tests and peak responses, growth measurements, and applicable risk factors.

      • Brain radiation or tumor resection:

    Continuation or Switch Therapy

    Continuation or switch therapy

    Approve for 1 year when the patient is currently receiving Ngenla or switching to Ngenla from another growth hormone agent, has been established on either therapy for ≥10 months, and meets ONE age-based continuation pathway.

    ALL of the following

    • Patient is currently receiving Ngenla or is switching to Ngenla from another growth hormone agent and has been established on either therapy for ≥10 months.≥10 months
    • ONE age-based continuation pathway

      • Patient is younger than 12 years and height increased by ≥2 cm/year in the most recent year.≥2 cm/year

        Documentation required.

    Clinical Thresholds and Coding Values

    Peak Growth Hormone Response
    ThresholdPeak growth hormone response <10 ng/mL
    Qualifying stimulation-test agentsLevodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon
    Testing pathwayAt least two tests below the threshold, or at least one test below the threshold plus at least one growth hormone deficiency risk factor
    Height Relative to Population Mean
    ThresholdMore than 2 standard deviations below the population mean height for age and sex
    MeasurementPatient height compared with the average population height for the patient's age and sex

    Prior Authorization and Submission Requirements

    Prior Authorization

    Submit Ngenla for Prior Authorization

    Submit Ngenla for prior authorization as somatrogon-ghla subcutaneous injection (Ngenla®, Pfizer).

    • Product: Ngenla (somatrogon-ghla)
    • Route: subcutaneous injection
    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Ngenla. Coverage is subject to clinical review and the terms of the applicable benefit plan.

    Prior Authorization

    Specialist Prescribing or Consultation

    Initial approval requires Ngenla to be prescribed by, or prescribed in consultation with, a physician who specializes in the condition being treated.

    Ngenla and Indication Overview

    Ngenla (somatrogon-ghla) is a long-acting human growth hormone analog indicated for growth failure caused by inadequate growth hormone secretion in pediatric patients aged 3 years and older. Evaluation of pediatric growth hormone deficiency incorporates clinical and growth assessment, biochemical evaluation of the growth hormone–insulin-like growth factor axis, and radiologic assessment; markedly reduced height or height velocity may support identification of children appropriate for growth hormone therapy.

    Clinical Definitions

    Pediatric Growth Hormone Deficiency
    DefinitionA condition involving inadequate secretion of growth hormone
    Possible presentationImpaired linear growth or abnormal height velocity
    AssessmentDiagnosis incorporates clinical and auxologic assessment, biochemical testing of the growth hormone–insulin-like growth factor axis, and radiologic evaluation
    Ngenla
    ProductNgenla is a human growth hormone analog
    CompositionContains the amino acid sequence of human growth hormone with three added copies of the C-terminal peptide of human chorionic gonadotropin
    Pharmacologic effect

    Preferred Growth Hormone Product Requirement

    StepRequirement
    1Use preferred growth hormone products before approval of Ngenla, or meet an applicable exception under PSM028, PSM029, PSM030, or PSM031.
    Policy Summary
    PayerCigna
    PolicyGrowth Disorders - Ngenla Prior Authorization Policy
    Policy CodePolicy IP0577
    Change TypeModified
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionUse preferred growth hormone products before requesting Ngenla, or document an applicable exception under the relevant preferred-product policy.
    SourceLink
    On This Page
    Ngenla Coverage CriteriaInitial Pediatric TherapyContinuation or Switch TherapyClinical Thresholds and Coding ValuesPrior Authorization and Submission RequirementsNgenla and Indication OverviewClinical DefinitionsPreferred Growth Hormone Product Requirement
    Patient has the imaging triad of ectopic posterior pituitary, pituitary hypoplasia, and an abnormal pituitary stalk.

    Documentation required.

    Patient has undergone brain radiation or tumor resection and has either one qualifying stimulation test with a peak response <10 ng/mL or a deficiency in at least one other pituitary hormone, with endocrinologist prescribing or consultation.
    <10 ng/mL or at least one other pituitary hormone deficiency

    Documentation required.

  1. Congenital hypopituitarism: Patient has congenital hypopituitarism and has either one qualifying stimulation test with a peak response <10 ng/mL, a deficiency in at least one other pituitary hormone, or the imaging triad of ectopic posterior pituitary, pituitary hypoplasia, and abnormal pituitary stalk, with endocrinologist prescribing or consultation.<10 ng/mL or qualifying pituitary finding

    Documentation required.

  2. Multiple pituitary hormone deficiencies: Patient has at least three listed pituitary hormone deficiencies, or one qualifying stimulation test with a peak response <10 ng/mL, with endocrinologist prescribing or consultation.At least 3 deficiencies or <10 ng/mL

    Documentation required.

  3. Hypophysectomy: Patient has undergone hypophysectomy (surgical removal of the pituitary gland).
  4. Initial pediatric growth hormone deficiency therapy

    The revised initial pediatric growth hormone deficiency pathway requires ALL of the following.

    Initial pediatric growth hormone deficiency pathway

    • Patient is at least 3 years of age and younger than 18 years.
    • At least one growth hormone stimulation test was performed using levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon, and the peak growth hormone response to at least one test was <10 ng/mL.<10 ng/mL

      Documentation required.

    • At least one growth hormone deficiency risk factor is present.

      Examples include downward crossing of two major height percentiles, growth below the expected rate for age and sex, low IGF-1 and/or IGFBP-3, a very low provocative-test peak as defined by the prescriber, growth velocity below the 10th percentile, status post craniopharyngioma resection, optic nerve hypoplasia, or a growth hormone gene deletion.

    Patient is ≥12 years and <18 years, height increased by ≥2 cm/year in the most recent year, and epiphyses are open.≥2 cm/year; open epiphyses

    Documentation required.

    Continuation or switch to Ngenla

    Continuation or switching to Ngenla requires ALL of the following.

    Established therapy and response

    • Patient is currently receiving Ngenla or is switching to Ngenla from another growth hormone agent and has been established on either therapy for at least 10 months.≥10 months
    • Documentation shows height increased by at least 2 cm/year in the most recent year.≥2 cm/year

      Documentation required.

    • Epiphyses are open.

      Documentation required.

    Related requirement
    The criterion is paired with a qualifying one-year height-velocity or height-decrease finding
    One-Year Height Velocity
    ThresholdMore than 1 standard deviation below the mean for chronological age
    Measurement periodOne year
    Alternative pathwayOne-year height velocity more than 2 standard deviations below the mean for age and sex also qualifies under a separate pathway
    Height Decrease
    ThresholdA decrease of more than 0.5 standard deviation over one year
    Minimum agePatient is 2 years of age or older
    ApplicabilityThis is an alternative to the one-year height-velocity criterion for a patient whose height is more than 2 standard deviations below the population mean
    Sustained Height Velocity
    ThresholdMore than 1.5 standard deviations below the mean
    DurationSustained over two years
    Use in criteriaQualifies as a separate height-velocity pathway for pediatric growth hormone deficiency
    Continuation Height Increase
    ThresholdHeight increased by ≥2 cm/year in the most recent year
    PopulationPatients continuing Ngenla or switching to Ngenla from another growth hormone agent
    DocumentationHeight increase must be documented
    Established Therapy Duration
    DurationEstablished on Ngenla or another growth hormone agent for ≥10 months
    Applies toPatients currently receiving Ngenla or switching to Ngenla from another growth hormone agent
    Approval periodApprove for 1 year when a qualifying continuation pathway is met
    Revised Peak Growth Hormone Response
    Revised thresholdAt least one growth hormone stimulation test with a peak response <10 ng/mL
    Additional requirementAt least one growth hormone deficiency risk factor must also be present under the revised pathway
    Age rangeAt least 3 years of age and younger than 18 years
    Annual Height Increase Documentation
    Height increaseAt least 2 cm/year in the most recent year
    Required documentationDocumentation of the annual height increase is required for continuation or switching therapy
    Additional documentationOpen epiphyses must also be documented for patients age 12 years and younger than 18 years
    • For growth hormone deficiency, prescribing or consultation with an endocrinologist is required in the applicable clinical pathways.
    Step Therapy

    Preferred Specialty Management Applies

    Ngenla is subject to preferred specialty management. Before requesting Ngenla, review the applicable preferred-product policy for the member's plan segment and document any required exception.

    • Individual and Family Plans: PSM028
    • Standard and Performance Prescription Drug List Plans: PSM029
    • Value/Advantage and Total Savings Prescription Drug List Plans: PSM030
    • Legacy Prescription Drug List Plans: PSM031
    Prior Authorization

    Clinical Prior Authorization Review

    All prior authorization reviews are directed to a clinician for verification of criteria, including a pharmacist, nurse, or other appropriate clinician.

    • Submit sufficient clinical information for clinician review.
    • Approval duration follows the applicable policy criteria.
    Step Therapy

    Preferred Product Management by Plan Segment

    Meet the preferred-product management requirements applicable to the member's plan segment before Ngenla approval. Consult the relevant preferred specialty management policy for product criteria and exceptions.

    • Plan-specific preferred-product requirements may differ.
    • Document the preferred-product trial or an applicable exception when required.
    Step Therapy

    Preferred Growth Hormone Product First

    Use a preferred growth hormone product first when required by the applicable plan policy. Ngenla approval may require satisfaction of preferred-product criteria or an approved exception.

    • Review PSM028, PSM029, PSM030, or PSM031 as applicable.
    • Do not bypass step therapy without documenting a policy-recognized exception.
    Documentation Required

    Submit Patient-Specific Documentation

    Provide patient-specific documentation for each criterion marked documentation required. Documentation may include chart notes, prescription claims records, prescription receipts, or other supporting information.

    • All documentation must include patient-specific identifying information.
    • If the required documentation was received during a prior coverage review, that requirement is considered met.
    Documentation Required

    Document Clinical Criteria

    For initial pediatric growth hormone deficiency therapy, document the applicable clinical pathway: stimulation-test results and peak growth hormone response, growth or height criteria, relevant risk factors, other pituitary hormone deficiencies, congenital hypopituitarism or imaging findings, and specialist involvement.

    • Patient must be at least 3 years old and younger than 18 years old for the covered pediatric indication.
    • Stimulation testing uses levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon, with the applicable peak response below 10 ng/mL.
    • Document growth or height criteria, including height standard deviations, height velocity, or height-for-age changes as applicable.
    • For brain radiation or tumor resection, document the required stimulation-test result or other pituitary hormone deficiency and endocrinology involvement.
    • For congenital hypopituitarism, document the applicable stimulation-test result, other pituitary hormone deficiency, or imaging triad of ectopic posterior pituitary, pituitary hypoplasia, and abnormal pituitary stalk.
    • For multiple pituitary hormone deficiencies, document three or more specified deficiencies or the applicable stimulation-test result, with endocrinology involvement.
    Documentation Required

    Document Continuation Growth

    For continuation of Ngenla or a switch from another growth hormone agent after the patient has been established on either therapy for at least 10 months, document the required recent growth and skeletal-maturity findings.

    • Patient younger than 12 years: height increased by at least 2 cm per year in the most recent year.
    • Patient at least 12 and younger than 18 years: height increased by at least 2 cm per year in the most recent year and epiphyses are open.
    • Documentation is required for the annual height increase and, when applicable, open epiphyses.
    Billing Rule

    Use Covered Codes and Diagnoses

    Use covered diagnosis and procedure codes that are current as of the submission date and appropriate to the requested service. Claims submitted without covered codes under the applicable policy may be denied as not covered.

    • Use the most appropriate codes for the effective date of submission.
    • Do not bill Ngenla for diagnoses or conditions not covered by the policy.
    Denial Risk

    Non-Approved or Enhancement Use

    Ngenla is not medically necessary for uses outside the covered FDA-approved indication. Growth hormone is not FDA-approved for anti-aging, longevity, cosmetic use, athletic performance enhancement, or bodybuilding in non-athletes.

    • Federal law prohibits dispensing growth hormone for non-approved purposes.
    • A pharmacy may decline to dispense prescriptions associated with anti-aging, longevity, rejuvenation, cosmetic, performance-enhancement, or sports-medicine use.
    Denial Risk

    Criteria Not Met: Denial Risk

    Initial or continuation/switch approval may be denied when the applicable clinical criteria are not met or required supporting documentation is missing.

    • Initial therapy: the applicable stimulation-test, growth/height, risk-factor, pituitary deficiency, imaging, hypophysectomy, and endocrinology requirements must be satisfied.
    • Continuation or switch: the patient must have been established on therapy for at least 10 months and meet the applicable annual height-increase and open-epiphyses requirements.
    • The requested use must be within the covered pediatric indication of age 3 years to younger than 18 years.
    Denial Risk

    Preferred Product Requirement: Denial Risk

    Ngenla may be denied when required preferred-product management is not completed or when the request does not meet an applicable exception under the member's plan segment.

    • Review the applicable preferred specialty management policy before submission.
    • Document prior preferred-product use, contraindication, intolerance, or another recognized exception when applicable.
    Denial Risk

    Insufficient Deficiency Evidence: Denial Risk

    Insufficient evidence of growth hormone deficiency may result in denial. Submit the required stimulation-test results and peak response, risk-factor evidence, congenital hypopituitarism findings, pituitary hormone deficiencies, imaging, and specialist documentation for the selected pathway.

    • Where required, document at least two stimulation tests with peak responses below 10 ng/mL, or one test below 10 ng/mL plus at least one growth hormone deficiency risk factor.
    • For brain radiation or tumor resection, document one qualifying stimulation test or at least one other pituitary hormone deficiency.
    • For congenital hypopituitarism, document one qualifying stimulation test, another pituitary hormone deficiency, or the specified imaging triad.
    • For multiple pituitary hormone deficiencies, document three or more specified deficiencies or the qualifying stimulation-test pathway.
    • Document prescription by or consultation with an endocrinologist when required.
    Denial Risk

    Missing Continuation Documentation: Denial Risk

    Continuation or switch requests may be denied when the required growth response or skeletal-maturity documentation is missing.

    • Document height increase of at least 2 cm per year in the most recent year.
    • For patients at least 12 and younger than 18 years, also document that the epiphyses are open.
    • Required documentation must be patient-specific.
    The added C-terminal peptides extend Ngenla's half-life
    Multiple Pituitary Hormone Deficiency
    DefinitionGrowth hormone deficiency occurring with other pituitary hormone deficiencies
    Related termsHypopituitarism, panhypopituitarism, or multiple pituitary hormone deficiency
    Listed deficienciesGrowth hormone, adrenocorticotropic hormone, thyroid-stimulating hormone, gonadotropin, and prolactin deficiencies
    Hypophysectomy
    DefinitionSurgical removal of the pituitary gland
    Coverage pathwayA patient who has undergone hypophysectomy is listed as a qualifying initial-therapy pathway
    Clinical contextThe procedure is identified separately from the stimulation-test and hormone-deficiency pathways
    Growth Hormone Stimulation Test
    DefinitionTesting used to assess peak growth hormone response
    AgentsLevodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon
    Relevant resultA qualifying stimulation test has a peak growth hormone response below 10 ng/mL
    Related Terminology and Conditions
    TerminologyGrowth hormone deficiency may be referred to as hypopituitarism, panhypopituitarism, or multiple pituitary hormone deficiency when it occurs with other pituitary hormone deficiencies
    Related conditionsOther pituitary hormone deficiencies may include adrenocorticotropic hormone, thyroid-stimulating hormone, gonadotropin, or prolactin deficiency
    Gonadotropin terminologyLuteinizing hormone and follicle-stimulating hormone deficiencies are counted as one deficiency